EMA Recommends Granting a Marketing Authorisation for Relugolix
It is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
A Follow-Up Not Inferior to Radioiodine Ablation in Patients with Low-Risk Differentiated Thyroid Cancer Undergoing Thyroidectomy
Findings from the ESTIMABL2 study
First-Line Treatment with Ribociclib plus Letrozole Shows a Significant Overall Survival Benefit in HR-positive, HER2-negative Advanced Breast Cancer
Findings from the final overall survival analysis in the MONALEESA-2 study
Short-Term Radiotherapy with Preoperative Chemotherapy Followed by Surgery is Efficacious with Acceptable Toxicity in Locally Advanced Rectal Cancer
Findings from the randomised, phase III STELLAR study
FDA Approves Olaparib for Adjuvant Treatment of High-Risk Early Breast Cancer
Patients must be selected for therapy based on an FDA-approved companion diagnostic for olaparib
EMA Adopts a Revised Opinion for Enfortumab Vedotin After Further Safety Information Emerged During the Decision-Making Process
It is intended for the treatment of adult patients with urothelial cancer
Risk Estimates of Small Bowel Cancer in Inflammatory Bowel Disease
Findings from a large, prospective cohort study of patients with inflammatory bowel disease diagnosed in Norway and Sweden
Survivors of Childhood, Adolescent, and Young Adult Cancer Not at Increased Risk of Testing Positive for COVID-19, nor for Serious Sequelae when Contracting Infection
Findings from the first population-based study to examine SARS-CoV-2 infections in survivors of childhood, adolescent, and young adult cancer compared with matched population controls
FDA Approves Neoadjuvant Nivolumab and Platinum-Doublet Chemotherapy for Early-Stage NSCLC
Efficacy was evaluated in CHECKMATE-816 study
German National Network Genomic Medicine Suggests a Novel Classification of Atypical EGFR Mutations
Classifications is proposed according sensitivity of atypical EGFR mutations to tyrosine kinase inhibitors
EMA Recommends Extension of Therapeutic Indications for Abemaciclib
New indication concerns the use in patients with early breast cancer at high risk of recurrence
Addition of a Live Bacterial Product Enhances the Clinical Outcome in Patients with mRCC Treated with Nivolumab-Ipilimumab Combination
Promising clinical benefit associated with an enrichment of bacterial species, circulating cytokines and immune cell populations in responders